Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GCK | P35557 | 14/20 | 0.60 |
| ▸ | PTGER1 | P34995 | 2/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.46 |
| ▸ | NPC1 | O15118 | 3/20 | 0.46 |
| ▸ | RAB9A | P51151 | 3/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | STAT3 | P40763 | 1/20 | 0.46 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.45 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.45 |
| ▸ | RELA | Q04206 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2657334 | 0.91 | GCK (0.66) | GCKPTGER1SMN1; SMN2NPC1RAB9A | |
| SCHEMBL2659579 | 0.85 | GCK (0.59) | GCKPTGER1 | |
| SCHEMBL2658405 | 0.84 | GCK (0.61) | GCK | |
| SCHEMBL2657112 | 0.84 | GCK (0.60) | GCK | |
| SCHEMBL1426862 | 0.84 | GCK (0.68) | GCK | |
| SCHEMBL3303035 | 0.83 | GCK (0.67) | GCK | |
| SCHEMBL1427556 | 0.78 | GCK (0.61) | GCK | |
| SCHEMBL1427047 | 0.78 | GCK (0.58) | GCK | |
| SCHEMBL2656253 | 0.77 | GCK (0.66) | GCKPTGER1SMN1; SMN2NPC1RAB9A | |
| SCHEMBL1426983 | 0.76 | GCK (0.61) | GCKPTGER1SMN1; SMN2NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2197849-B1 | N- ( PYRAZOLE- 3 -YL) -BENZAMIDE DERIVATIVES AS GLUCOKINASE ACTIVATORS | MERCK PATENT GMBH (DE) | 2013-02-27 | — | — | EP | claimed |
| US-8236824-B2 | N-(pyrazole-3-yl)-benzamide derivatives as glucokinase activators | MERCK Patent Gesellschaft mit beschränkter Haftung (DE) | 2012-08-07 | — | — | US | claimed |
| CN-101821240-A | N- ( pyrazole- 3 -yl) -benzamide derivatives as glucokinase activators | MERCK PATENT GMBH | 2010-09-01 | — | — | CN | claimed |
| US-20100210690-A1 | N-(PYRAZOLE-3-YL)-BENZAMIDE DERIVATIVES AS GLUCOKINASE ACTIVATORS | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2010-08-19 | — | — | US | claimed |
| EP-2197849-B1 | N- ( PYRAZOLE- 3 -YL) -BENZAMIDE DERIVATIVES AS GLUCOKINASE ACTIVATORS | MERCK PATENT GMBH (DE) | 2013-02-27 | — | — | EP | disclosed |
| US-8236824-B2 | N-(pyrazole-3-yl)-benzamide derivatives as glucokinase activators | MERCK Patent Gesellschaft mit beschränkter Haftung (DE) | 2012-08-07 | — | — | US | disclosed |
| US-8236824-B2 | N-(pyrazole-3-yl)-benzamide derivatives as glucokinase activators | MERCK Patent Gesellschaft mit beschränkter Haftung (DE) | 2012-08-07 | — | — | US | disclosed |
| US-8236824-B2 | N-(pyrazole-3-yl)-benzamide derivatives as glucokinase activators | MERCK Patent Gesellschaft mit beschränkter Haftung (DE) | 2012-08-07 | — | — | US | disclosed |
| CN-101821240-A | N- ( pyrazole- 3 -yl) -benzamide derivatives as glucokinase activators | MERCK PATENT GMBH | 2010-09-01 | — | — | CN | disclosed |
| US-20100210690-A1 | N-(PYRAZOLE-3-YL)-BENZAMIDE DERIVATIVES AS GLUCOKINASE ACTIVATORS | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2010-08-19 | — | — | US | disclosed |
| US-20100210690-A1 | N-(PYRAZOLE-3-YL)-BENZAMIDE DERIVATIVES AS GLUCOKINASE ACTIVATORS | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2010-08-19 | — | — | US | disclosed |
| US-20100210690-A1 | N-(PYRAZOLE-3-YL)-BENZAMIDE DERIVATIVES AS GLUCOKINASE ACTIVATORS | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2010-08-19 | — | — | US | disclosed |
| EP-2197849-A1 | N- ( PYRAZOLE- 3 -YL) -BENZAMIDE DERIVATIVES AS GLUCOKINASE ACTIVATORS | Merck Patent GmbH (DE) | 2010-06-23 | — | — | EP | disclosed |
| WO-2009046802-A1 | N- ( PYRAZOLE- 3 -YL) -BENZAMIDE DERIVATIVES AS GLUCOKINASE ACTIVATORS | MERCK PATENT GMBH (DE) | 2009-04-16 | — | — | WO | disclosed |
| WO-2009046802-A1 | N- ( PYRAZOLE- 3 -YL) -BENZAMIDE DERIVATIVES AS GLUCOKINASE ACTIVATORS | MERCK PATENT GMBH (DE) | 2009-04-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100210690-A1 | N-(PYRAZOLE-3-YL)-BENZAMIDE DERIVATIVES AS GLUCOKINASE ACTIVATORS | GCKR, HK1, GCK | GCK 3/4885PTGER1 489/4885SMN1; SMN2 2801/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.